Chest
-
COPD Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol (IND) is a once daily long acting beta 2 agonist (LABA). This study evaluated how IND can be introduced into real life treatment regimens for COPD in Israel. ⋯ Gabriel Izbicki: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium David Shitrit: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Meir Raz: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Zeev Vilayi-Weiler: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Gershon Fink: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Yehuda Schwarz: Consultant fee, speaker bureau, advisory committee, etc.: Advisor Honorarium Sari Lubin: Employee: Salary Lital Daniel: Employee: Salary Tamar Rachmilewitz: Employee: Salary Mordechai Kramer: Consultant fee, speaker bureau, advisory committee, etc.: Advisor HonorariumNo Product/Research Disclosure Information.
-
Pleural CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Patients with large pleural effusions often experience dramatic relief from dyspnea after thoracentesis. While this is well-recognized, the physiological basis for such relief remains poorly understood. One commonly held belief is that thoracentesis allows for lung reexpansion, ventilation of previously atelectatic lung, and improved ventilation-perfusion matching, subsequently leading to dyspnea relief. This contrasts with the concept of "length-tension inappropriateness," which posits chest wall mechanics best explain dyspnea relief. ⋯ Our case established that dyspnea relief after thoracentesis likely results from changes in chest wall mechanics and/or work of breathing. This observation has direct clinical implications and could inform therapeutic decisions.Reference #1: Brown NE et al. Changes in pulmonary mechanics and gas exchange following thoracentesis. Chest. 1978; 74: 540-42Reference #2: Estenne M et al. Mechanism of relief of dyspnea after thoracentesis in patients with large pleural effusions. Am J Med. 1983; 74(5):813-9Reference #3: Wang LM et al. Improved lung function after thoracentesis in patients with paradoxical movement of a hemidiaphragm secondary to a large pleural effusion. Respirology. 2007; 12(5):719-23DISCLOSURE: The following authors have nothing to disclose: Mary Klecka, Fabien MaldonadoNo Product/Research Disclosure Information.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Cystic fibrosis (CF) is a multisystemic disease characterized by a limited exercise capacity. Exercise training (ET) using systems that improve the adherence to pulmonary rehabilitation programs is a key factor to guarantee the benefits of this therapy. Our goal was to evaluate the efficacy of a long term domiciliary exercise program using the WiiTM video game platform as a training system in patients with CF. ⋯ The following authors have nothing to disclose: Tamara Del Corral Nuñez-Flores, Roberto Martinez Alejos, Angels Cebria i Iranzo, Jordi Vilaró, Roberto RabinovichNo Product/Research Disclosure Information.
-
Pleural Disease/Pleural Effusion PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To assess the discriminatory power of pleural ADA levels in pleural effusions lymphomas. - Define the cutoff level in these cases. ⋯ The following authors have nothing to disclose: Deisy Barrios Barreto, Esteban Perez Rodriguez, Carolina Gotera, Patricia Lazo Meneses, Paola Arrieta Narvaez, Rosa Mirambeaux Villalona, Salvador Diaz Lobato, Sagrario Mayoralas AlisesNo Product/Research Disclosure Information.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The most common autoimmune inflammatory demyelinating disease of the central nervous system is multiple sclerosis. It has a unique clinical feature of unpredictable exacerbations and remissions. Systemic infectious process is one of the important precipitating factors for multiple sclerosis exacerbation1. ⋯ Our case report reflects the association of a multiple sclerosis exacerbation with an underlying infectious process. The patient's neurological findings significantly improved following treatment of the empyema. Early detection and adequate treatment of systemic infection is a cornerstone of multiple sclerosis exacerbation management.Reference #1: Buljevac D, Flach HZ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952-960Reference #2: Correale J, Fiol M, et al. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652-659DISCLOSURE: The following authors have nothing to disclose: Debjit Saha, Jillian Cepeda, Daisha Hayden, Ari CimentNo Product/Research Disclosure Information.